Benlysta (belimumab) Disease Interactions
There are 4 disease interactions with Benlysta (belimumab):
Immunosuppressive agents (Includes Benlysta) ↔ infections
Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral
Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.
Immunosuppressive agents (Includes Benlysta) ↔ PML
Severe Potential Hazard, Moderate plausibility. Applies to: Immunodeficiency
Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.
Belimumab (Includes Benlysta) ↔ depression
Moderate Potential Hazard, Moderate plausibility. Applies to: Depression
Psychiatric events have been reported with the use of belimumab. Caution is recommended when prescribing this agent to patients with serious depression or suicidal behavior, history of depression, or other serious psychiatric disorders. Patients receiving belimumab should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes while on belimumab.
Belimumab (Includes Benlysta) ↔ vaccination
Moderate Potential Hazard, Moderate plausibility. Applies to: Vaccination
Live vaccines should not be given for 30 days before or concurrently with belimumab as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving belimumab or the effect of belimumab on new immunizations. Because of its mechanism of action, belimumab may interfere with the response to immunizations.
Benlysta (belimumab) drug interactions
There are 112 drug interactions with Benlysta (belimumab)
More about Benlysta (belimumab)
- Benlysta Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 26 Reviews
- Drug class: selective immunosuppressants
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.